Expertise in
5
conditions

Marie Essig

Montigny-sur-loing, FR 
Expertise in
5
conditions
Montigny-sur-loing, FR 

Overview

Marie Essig practices practicing medicine in Montigny-sur-loing, France.

Ms. Essig is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Chronic Kidney Disease, Diethylstilbestrol Syndrome, Goodpasture Syndrome, Kidney Transplant, and Liver Transplant.

She is actively involved in clinical research, co-authoring 109 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Montigny-sur-loing, France
Other Locations
Paris, France
Boulogne-billancourt, France
Versailles, France
Limoges, France
Inserm U1018, Équipe 5 CESP Et UVSQ, 16 Avenue Paul Vaillant Couturier, Villejuif, 94800, France
Nancy, France
Orleans, 45000, France
Rennes, France
Strasbourg, France
Tours, France
CHU Reims
Reims, France
Brest, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
Intervention Type: Other, Drug
Study Phase: Phase 3
Pharmacokinetic Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)
Pharmacokinetic Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug
Study Phase: Phase 4
Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation
Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Phase: Phase 4
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Spironolactone
Study Phase: Phase 3
Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors
Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors
Enrollment Status: Suspended
Publish Date: July 05, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

109 Total Publications

Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies.
Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies.
Journal: Kidney international reports
Published: July 23, 2025

Frequently Asked Questions about Marie Essig

Is Marie Essig a top-rated expert for Kidney Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Marie Essig is classified as an Advanced expert for Kidney Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marie Essig participate in research or clinical trials?

Yes. Marie Essig has published 109 articles and abstracts on conditions like Kidney Transplant. You can view a list of Marie Essig's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Essig's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile